1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Consensus
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
211.93 USD   +0.26%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on BIOGEN INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) BIOGEN INC.
Analyst Recommendations on BIOGEN INC.
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Maintains..
MT
04/28Wedbush Raises Biogen's Price Target to $188 From $185, Maintains Neutral Rating
MT
04/27UBS Adjusts Biogen Price Target to $244 From $269, Maintains Buy Rating
MT
More recommendations
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 211,93 $
Average target price 242,78 $
Spread / Average Target 14,6%
High Price Target 343,00 $
Spread / Highest target 61,8%
Low Price Target 185,00 $
Spread / Lowest Target -12,7%
Consensus detail
Consensus revision (last 18 months)